Boothbay Fund Management’s Fulcrum Therapeutics FULC Stock Holding History

Boothbay Fund Management’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.33M	Sell	303,988 -213,538	-41%	-$1.98M	0.03%	555
2025 Q4	$5.85M	Sell	517,526 -160,888	-24%	-$1.64M	0.09%	250
2025 Q3	$6.24M	Buy	678,414 +537,036	+380%	+$3.89M	0.09%	252
2025 Q2	$973K	Buy	141,378 +81,845	+137%	+$438K	0.02%	689
2025 Q1	$171K	Hold	59,533	–	–	﹤0.01%	1189
2024 Q4	$280K	Buy	59,533 +37,596	+171%	+$139K	0.01%	1089
2024 Q3	$78.3K	Buy	+21,937	New	+$163K	﹤0.01%	1475
2024 Q1	–	Sell	-11,730	Closed	-$79.2K	–	1694
2023 Q4	$79.2K	Buy	+11,730	New	+$52K	﹤0.01%	1456
2021 Q3	–	Sell	-29,050	Closed	-$304K	–	1995
2021 Q2	$304K	Sell	29,050 -21,834	-43%	-$221K	0.01%	1271
2021 Q1	$599K	Buy	50,884 +976	+2%	+$12.1K	0.02%	848
2020 Q4	$584K	Buy	+49,908	New	+$564K	0.02%	686

Other funds holding FULC

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

FTM

First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Boothbay Fund Management's FULC Position: Q1 2026 in Review

Boothbay Fund Management reduced its Fulcrum Therapeutics (FULC) stake by 41% in Q1 2026, selling an estimated $1.98M and leaving 303,988 shares worth $2.33M. The position accounts for 0.03% of the portfolio, ranked #555.

Boothbay Fund Management first reported a position in FULC in Q4 2020 and has held it in 11 quarters since. The position peaked at $6.24M in Q3 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

Boothbay Fund Management held 303,988 shares of Fulcrum Therapeutics worth $2.33M as of Q1 2026.
Boothbay Fund Management sold 213,538 Fulcrum Therapeutics shares in Q1 2026, an estimated $1.98M.
Fulcrum Therapeutics made up 0.03% of Boothbay Fund Management's portfolio in Q1 2026, its #555 holding.
Boothbay Fund Management first reported a position in Fulcrum Therapeutics in Q4 2020 and has held it in 11 quarters since.
Boothbay Fund Management's Fulcrum Therapeutics position peaked at $6.24M in Q3 2025.
169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.